ReviewCardiovascular drugs and therapy2026
MicroRNAs and Long Non-coding RNAs Associated With Sirtuin Pathways in Myocardial Ischemia/Reperfusion Injury.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Myocardial ischemia/reperfusion (I/R) injury contributes significantly to post-infarction cardiac dysfunction and heart failure, despite advances in reperfusion therapies. Among molecular regulators of I/R injury, sirtuins (SIRTs) play key roles in modulating oxidative stress, apoptosis, inflammation, and mitochondrial function. Increasing evidence highlights the regulatory role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in controlling sirtuin signaling in the ischemic myocardium. This review synthesizes current preclinical findings on miRNA- and lncRNA-mediated regulation of SIRTs in myocardial I/R injury model. It further highlights the emerging mechanistic pathways through which ncRNAs influence sirtuin activity and discusses their potential relevance as therapeutic targets. Several miRNAs aggravate cardiomyocyte damage by downregulating SIRTs, while lncRNAs exert protective effects through miRNA sponging and sirtuin upregulation. These regulatory axes influence key cellular processes, including mitochondrial homeostasis, pyroptosis, apoptotic signaling and regulation of the inflammasome pathways. Additionally, the network analysis identified apoptosis as the most frequently involved process, with SIRT1 and miR-29a, miR-34a, and miR-217-5p showing the highest degree of connectivity. Despite growing mechanistic insight, translation into clinical practice is hindered by the scarcity of human studies and randomized trials. Moreover, current knowledge regarding miRNAs is limited to only three sirtuin isoforms, underscoring the need for further investigation. Understanding the ncRNA–SIRT axis may offer novel therapeutic strategies for mitigating myocardial I/R injury.
Indexed as
Identifiers
41849042What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.